JPMorgan Chase & Co. Raises Position in Corcept Therapeutics Incorporated $CORT

JPMorgan Chase & Co. grew its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 223.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 849,864 shares of the biotechnology company’s stock after buying an additional 587,053 shares during the quarter. JPMorgan Chase & Co.’s holdings in Corcept Therapeutics were worth $70,632,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Royal Bank of Canada boosted its holdings in Corcept Therapeutics by 18.9% in the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after purchasing an additional 2,444 shares during the period. Amundi acquired a new stake in Corcept Therapeutics in the 1st quarter valued at about $450,000. NewEdge Advisors LLC purchased a new position in shares of Corcept Therapeutics in the 1st quarter valued at about $518,000. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Corcept Therapeutics by 7.9% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,129 shares of the biotechnology company’s stock worth $230,000 after buying an additional 230 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Corcept Therapeutics by 1.8% during the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock worth $730,000 after buying an additional 180 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $36.48 on Wednesday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $117.33. The firm has a market capitalization of $3.84 billion, a P/E ratio of 41.46 and a beta of 0.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. The company’s fifty day moving average price is $47.21 and its 200 day moving average price is $66.45.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same period in the previous year, the business posted $0.26 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, sell-side analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CORT shares. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research note on Wednesday, December 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Truist Financial set a $50.00 price target on Corcept Therapeutics in a research note on Wednesday, December 31st. Finally, HC Wainwright lowered their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Hold” and an average price target of $77.17.

Insider Transactions at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $79.53, for a total value of $397,650.00. Following the completion of the sale, the insider directly owned 10,277 shares of the company’s stock, valued at approximately $817,329.81. This represents a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares in the company, valued at $50,474.45. The trade was a 94.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 125,000 shares of company stock worth $8,301,450. 20.50% of the stock is owned by corporate insiders.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company issued audited Q4 and full‑year 2025 results and an optimistic outlook that management characterized as positive for the business — this messaging likely supports intraday buying interest. Corcept Therapeutics Posts Strong 2025 Results
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to a $900 million – $1.0 billion range; the midpoint sits slightly below some sell‑side consensus, leaving room for mixed analyst reactions and uncertainty about near‑term estimates. FY‑2026 Guidance / Press Release
• Negative Sentiment: Reported Q4 EPS of $0.20 missed consensus ($0.27) and revenue of ~$202.1M missed estimates (~$254.9M). The beat/miss details explain part of today’s volatility and investor caution. Earnings Details / Conference Call
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff applicants in a securities class action covering Oct. 31, 2024–Dec. 30, 2025, alleging Corcept failed to disclose FDA concerns about the adequacy of evidence for the relacorilant NDA — this legal overhang is materially negative and has been cited as a driver of a prior ~50% share decline. Representative notices: Robbins LLP and Rosen Law Firm. Robbins LLP Class Action Notice Rosen Law Firm Notice
• Negative Sentiment: Analyst reaction: HC Wainwright cut its price target (reflecting changed expectations post‑NDA/FDA disclosure), adding downward pressure on sentiment. HC Wainwright PT Cut

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.